HC Wainwright set a $18.00 price target on Aduro Biotech, Inc. (NASDAQ:ADRO) in a report released on Wednesday. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other brokerages have also commented on ADRO. Zacks Investment Research lowered Aduro Biotech from a buy rating to a hold rating in a report on Wednesday, August 2nd. BidaskClub lowered Aduro Biotech from a buy rating to a hold rating in a report on Wednesday, August 2nd. Canaccord Genuity set a $30.00 price target on Aduro Biotech and gave the stock a buy rating in a report on Thursday, August 3rd. Cowen and Company began coverage on Aduro Biotech in a report on Tuesday, July 18th. They set an outperform rating for the company. Finally, William Blair restated an outperform rating on shares of Aduro Biotech in a research note on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. Aduro Biotech has an average rating of Buy and a consensus price target of $19.14.

Shares of Aduro Biotech (NASDAQ ADRO) traded up $0.42 during mid-day trading on Wednesday, reaching $7.95. 412,491 shares of the company’s stock were exchanged, compared to its average volume of 507,949. Aduro Biotech has a twelve month low of $6.01 and a twelve month high of $15.52.

Aduro Biotech (NASDAQ:ADRO) last issued its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). Aduro Biotech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The business had revenue of $3.79 million for the quarter, compared to analyst estimates of $4.04 million. During the same quarter last year, the firm earned ($0.54) earnings per share. The firm’s quarterly revenue was up .0% compared to the same quarter last year. sell-side analysts anticipate that Aduro Biotech will post -1.28 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “HC Wainwright Reiterates $18.00 Price Target for Aduro Biotech, Inc. (ADRO)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/hc-wainwright-reiterates-18-00-price-target-for-aduro-biotech-inc-adro/1678362.html.

In other Aduro Biotech news, insider Jennifer Lew sold 6,600 shares of the stock in a transaction on Monday, August 7th. The stock was sold at an average price of $12.17, for a total transaction of $80,322.00. Following the completion of the transaction, the insider now directly owns 49,195 shares in the company, valued at $598,703.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Blaine Templeman sold 3,557 shares of the stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $10.99, for a total value of $39,091.43. Following the transaction, the vice president now owns 65,275 shares of the company’s stock, valued at $717,372.25. The disclosure for this sale can be found here. Insiders have sold 342,745 shares of company stock valued at $3,956,397 over the last quarter. Corporate insiders own 6.60% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its stake in Aduro Biotech by 283.7% during the second quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock worth $4,244,000 after acquiring an additional 275,295 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Aduro Biotech by 5.7% during the first quarter. Schwab Charles Investment Management Inc. now owns 145,112 shares of the biotechnology company’s stock worth $1,560,000 after purchasing an additional 7,812 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Aduro Biotech by 2.1% during the first quarter. Vanguard Group Inc. now owns 2,382,916 shares of the biotechnology company’s stock worth $25,617,000 after purchasing an additional 48,840 shares during the last quarter. PDT Partners LLC bought a new stake in shares of Aduro Biotech during the second quarter worth $570,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Aduro Biotech by 3.8% during the first quarter. Bank of New York Mellon Corp now owns 148,166 shares of the biotechnology company’s stock worth $1,593,000 after purchasing an additional 5,470 shares during the last quarter. Hedge funds and other institutional investors own 35.24% of the company’s stock.

Aduro Biotech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Analyst Recommendations for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.